Real-World Evidence of Improved Patient Outcomes with Reslizumab in Adults with Severe Eosinophilic Asthma (SEA): Subgroup Analyses of Patients Using Maintenance Oral Corticosteroids (OCS) Prior to Treatment Initiation

Effectiveness of reslizumab in U.S. clinical practice was demonstrated in a real-world study. Here we present data in the subgroup of patients using maintenance OCS therapy pre- and post-reslizumab treatment. A multicenter, retrospective chart review, collating patient-level data on adults with SEA receiving reslizumab for ≥7 months. Outcomes analyzed 6 months pre- and post-reslizumab treatment included maintenance OCS use, healthcare resource usage (HRU), CAEs, FEV1 percent predicted (FEV1PP), and Asthma Control Test (ACT) scores. Baseline characteristics, including mean±SD blood eosinophil counts of 528±378 cells/μL, in 37 patients receiving maintenance OCS pre- and post-reslizumab treatment initiation suggested greater asthma severity versus the full study sample (N=215). Post-reslizumab, 19 (51.4%) patients discontinued OCS therapy within 7 months, while 21 (56.8%) patients remained on OCS therapy for ≥4 months but reduced mean OCS dose from 20.6 mg/day to 15.5 mg/day. Patients with any CAE (78.4% vs 35.1%) and average number of CAEs per patient (1.59 vs 0.49) were significantly reduced (both p<0.001) post-reslizumab. Significant improvements in FEV1PP (60.2% vs 66.7%; p=0.008) and ACT scores (14.4 vs 18.6; p<0.001), and significant reductions in asthma-related HRU were reported: inpatient admissions, 37.8% vs 2.7% (p<0.001), mean days hospitalized (1.94±3.98 vs 0.12±0.70); ER visits, 73.0% vs 37.8% (p<0.001); urgent care visits, 40.6% vs 12.5% (p=0.007); unscheduled outpatient visits, 75.0% vs 55.6% (p=0.035). In SEA patients using OCS maintenance therapy in the real-world setting, more than half discontinued OCS within 7 months after starting reslizumab. Reslizumab treatment was associated with improved symptom control and asthma-related HRU reduction.